AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute.
Smith
Sidney C
SC
Allen
Jerilyn
J
Blair
Steven N
SN
Bonow
Robert O
RO
Brass
Lawrence M
LM
Fonarow
Gregg C
GC
Grundy
Scott M
SM
Hiratzka
Loren
L
Jones
Daniel
D
Krumholz
Harlan M
HM
Mosca
Lori
L
Pearson
Thomas
T
Pfeffer
Marc A
MA
Taubert
Kathryn A
KA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D050197:Atherosclerosis / Q000150:complications / Q000628:therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000150:complications / Q000628:therapy*; D003920:Diabetes Mellitus / Q000628:therapy; D050171:Dyslipidemias / Q000628:therapy; D015438:Health Behavior; D006401:Hematologic Agents / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007252:Influenza Vaccines; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009043:Motor Activity; D009765:Obesity / Q000628:therapy; D016540:Smoking Cessation
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D006401:Hematologic Agents; D000960:Hypolipidemic Agents; D007252:Influenza Vaccines; D000451:Mineralocorticoid Receptor Antagonists